Oxford Immunotec Schedules Third Quarter 2014 Earnings Release and Conference Call for November 4, 2014
(Thomson Reuters ONE) -
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 24, 2014 (GLOBE NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it plans to
release third quarter 2014 financial results prior to market open on Tuesday,
November 4, 2014. Dr. Peter Wrighton-Smith, Chief Executive Officer and Rick
Altieri, Chief Financial Officer will host a conference call to review the
Company's results at 8:00 a.m. Eastern Time the same day. The call will be
concurrently webcast.
To listen to the conference call on your telephone please dial (855) 363-5047
for United States callers and +1 (484) 365-2897 for international callers and
reference confirmation code 25979461, approximately ten minutes prior to start
time. To access the live audio webcast or subsequent archived recording, visit
the Investor Relations section of Oxford Immunotec's website at
http://www.oxfordimmunotec.com. The replay will be available on the Company's
website for approximately 90 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
committed to improving patient care by providing advanced, innovative tests in
the field of immunology. The proprietary T-SPOT(®) technology platform measures
the responses of specific immune cells, known as T cells, to inform the
diagnosis, prognosis and monitoring of patients with immunologically controlled
diseases. T cells are a central component of the human body's immune system, and
are implicated in the control and progression of many medical conditions,
including certain types of infectious diseases, cancers and autoimmune diseases.
The Company's initial product developed using the T-SPOT technology platform is
the T-SPOT.TB test, which is used to test for latent tuberculosis infection. The
T-SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The Company is headquartered near Oxford, UK and in Marlborough, MA.
Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley(at)oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer,
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri(at)oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
oxfordimmunotec(at)westwicke.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
[HUG#1865754]
Unternehmensinformation / Kurzprofil:
Datum: 24.10.2014 - 19:10 Uhr
Sprache: Deutsch
News-ID 346851
Anzahl Zeichen: 3458
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Schedules Third Quarter 2014 Earnings Release and Conference Call for November 4, 2014"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
